Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Theriva Biologics, Inc. (TOVX)

Theriva Biologics doses first patient in VIRAGE2 trial of repeated VCN-01 dosing

Neutral Impact 3 of 5 product/contract Written later

Theriva Biologics said it dosed the first patient in VIRAGE2, a small Phase 2a proof-of-concept study of more frequent repeated dosing of VCN-01 in first-line metastatic pancreatic cancer patients. The study will enroll 6 evaluable patients at a single site in Spain, with enrollment expected to finish in H2 2026 and initial data expected by Q3 2027. The filing reports no revenue, earnings or financial results, and the study is not formally powered to assess clinical efficacy.

Key points

  • First patient dosed in VIRAGE2, announced August 6, 2026
  • Study planned for 6 evaluable patients at a single site in Spain
  • Enrollment expected to be completed in H2 2026; initial pharmacodynamic and safety data expected by Q3 2027
  • Results are intended to inform the VCN-01 dosing regimen for a possible future Phase 3 trial

The filing

CompanyTheriva Biologics, Inc. (TOVX)
Form8-K, current report
Filed with the SECAug 6, 2026, 8:10 AM ET
Accession number0001104659-26-091674

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.